Valuation Metrics and Recent Changes
Alkem Laboratories, a mid-cap player in the Pharmaceuticals & Biotechnology sector, currently trades at ₹5,421.65, marginally down by 0.17% from its previous close of ₹5,431.05. The stock’s 52-week range spans from ₹4,716.75 to ₹5,933.00, indicating a relatively stable price band over the past year.
Most striking is the recent upgrade in the company’s valuation grade from fair to attractive, driven primarily by its price-to-earnings (P/E) ratio and price-to-book value (P/BV) metrics. The P/E ratio stands at 26.77, which, while higher than some peers, is considered reasonable given Alkem’s consistent earnings growth and return metrics. The P/BV ratio is 4.68, signalling a premium but justified by the company’s strong return on equity (ROE) of 17.48% and return on capital employed (ROCE) of 19.58%.
Other valuation multiples such as EV to EBIT (24.49) and EV to EBITDA (21.37) also reflect a premium valuation, yet remain within an attractive range relative to the sector’s growth prospects and Alkem’s operational efficiency.
Comparative Analysis with Peers
When benchmarked against key competitors, Alkem’s valuation appears competitive. Zydus Lifesciences and Lupin, both rated attractive, trade at P/E ratios of 20.33 and 18.61 respectively, with EV to EBITDA multiples of 13.69 and 11.87. While Alkem’s multiples are higher, its PEG ratio of 2.32 suggests a balanced growth-to-valuation trade-off compared to Lupin’s notably low PEG of 0.25, which may reflect differing growth trajectories or market perceptions.
Conversely, companies like Mankind Pharma and Laurus Labs are classified as expensive or very expensive, with P/E ratios soaring above 50 and EV to EBITDA multiples exceeding 29 and 45 respectively. This positions Alkem as a more reasonably valued option within the mid-cap pharmaceutical space, especially given its solid fundamentals.
Stock Performance Versus Sensex
Alkem’s stock performance over various time horizons underscores its resilience and growth potential. Year-to-date, the stock has declined by 1.52%, a modest underperformance relative to the Sensex’s sharper fall of 9.53%. Over the past year, Alkem has delivered an impressive 11.80% return, contrasting with the Sensex’s negative 6.83% return. Longer-term returns are even more compelling, with three-year and five-year gains of 62.15% and 72.64% respectively, significantly outpacing the Sensex’s 22.42% and 45.68% returns. Over a decade, Alkem’s return of 292.33% dwarfs the benchmark’s 192.07%, highlighting the company’s sustained value creation.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Quality and Dividend Yield
Alkem’s financial quality remains robust, supported by a dividend yield of 0.94%, which, while modest, aligns with the company’s reinvestment strategy to fuel growth. The company’s ROCE of 19.58% and ROE of 17.48% are indicative of efficient capital utilisation and profitability, reinforcing the valuation upgrade.
Its EV to capital employed ratio of 4.79 and EV to sales of 4.37 further demonstrate operational efficiency and a balanced capital structure, factors that contribute to investor confidence despite the stock’s slight recent price softness.
Market Sentiment and Rating Changes
MarketsMOJO’s proprietary Mojo Score for Alkem stands at 41.0, reflecting a cautious stance with a Sell grade, downgraded from Hold on 11 May 2026. This rating change suggests that while valuation metrics have improved, other factors such as momentum or sector headwinds may temper near-term enthusiasm.
Nonetheless, the shift in valuation grade to attractive signals that the stock’s price now offers a more favourable entry point relative to its historical averages and peer group, potentially appealing to value-oriented investors seeking exposure to the pharmaceuticals sector’s growth story.
Alkem Laboratories Ltd or something better? Our SwitchER feature analyzes this mid-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Valuation Context and Investor Implications
Alkem’s current valuation multiples, while elevated compared to some peers, are justified by its superior return ratios and consistent earnings growth. The P/E ratio of 26.77, though above the sector average, is supported by a PEG ratio of 2.32, indicating that the stock’s price growth is in line with earnings expansion.
Investors should note that the pharmaceutical sector is subject to regulatory risks and competitive pressures, which may impact near-term momentum. However, Alkem’s strong fundamentals and attractive valuation grade upgrade suggest a favourable risk-reward profile for medium to long-term investors.
Comparatively, stocks like Mankind Pharma and Laurus Labs, despite commanding higher valuations, carry greater risk premiums, making Alkem a more balanced choice within the mid-cap pharmaceutical universe.
Conclusion
In summary, Alkem Laboratories Ltd’s recent valuation upgrade from fair to attractive reflects a meaningful shift in price attractiveness, supported by solid financial metrics and superior long-term returns relative to the Sensex. While the Mojo Score downgrade to Sell signals caution, the company’s fundamentals and relative valuation position it as a compelling option for investors seeking exposure to the Pharmaceuticals & Biotechnology sector at a reasonable price point.
Market participants should weigh the improved valuation against sector dynamics and company-specific factors to make informed investment decisions.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
